Desert Pacific Mental Illness Research, Education, and Clinical Center Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2012
NCT01738698
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (1)

lisdexamfetamine (vyvanse) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Schizophrenia (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 1